ホーム>>Signaling Pathways>> Immunology/Inflammation>> Aryl Hydrocarbon Receptor>>Tapinarof (WBI 1001)

Tapinarof (WBI 1001)

カタログ番号GC31732

タピナロフ (WBI 1001) (WBI-1001) は、13 nM の EC50 を持つ天然のアリール炭化水素受容体 (AhR) アゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

Tapinarof (WBI 1001) 化学構造

Cas No.: 79338-84-4

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$89.00
在庫あり
5mg
$81.00
在庫あり
10mg
$135.00
在庫あり
25mg
$258.00
在庫あり
50mg
$405.00
在庫あり
100mg
$675.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tapinarof is a natural aryl hydrocarbon receptor (AhR) agonist with an EC50 of 13 nM.

Tapinarof activates the AhR pathway through direct binding. Tapinarof dose-dependently induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) (EC50=0.16 nM)[1].

Tapinarof acts through AhR to reduce inflammation in IMQ-treated mice. AhR-sufficient mice on a C57Bl/6 background exhibit a reduced clinical score after treatment with Tapinarof or 6-formylindolo(3,2-b)carbazole (FICZ). In contrast, AhR KO mice do not respond to the anti-inflammatory effects of Tapinarof. FICZ is used as a comparator in these studies and yields similar results, with dramatically reduced inflammatory responses in wild-type, but not AhR KO mice[1].

[1]. Smith SH, et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017 Oct;137(10):2110-2119.

レビュー

Review for Tapinarof (WBI 1001)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tapinarof (WBI 1001)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.